Hartford Business Journal

Health Care www.HartfordBusiness.com decemBer 26, 2016 • Hartford Business Journal 43 BOOK OF LISTS & ECONOMIC FORECAST 2016-2017 Largest bioscience/biotechnology companies in Connecticut (Ranked by number of employees as of March 2016) Rank Company Headquarters No. of employees in CT Bioscience sub categories Focus Year founded Top executive 1 Pfizer Inc. 558 Eastern Point Road Groton, CT 06340 860-441-4100; www.pfizer.com New York, NY 3,000 Pharmaceuticals Medicinal chemistry, pharmacokinetics, dynamics and metabolism, pharmaceutical sciences, clinical trials, drug safety, comparative medicine, regulatory 1849 Ian C. Read Chairman & CEO 2 Boehringer Ingelheim Pharmaceuticals Inc. 900 Ridgebury Road Ridgefield, CT 06877 800-344-3095; us.boehringer- ingelheim.com Ridgefield, CT 2,700 (1) Pharmaceuticals Development and manufacture of human and animal healthcare products 1885 Paul R. Fonteyne President & CEO, USA 3 Alexion Pharmaceuticals Inc. 100 College St. New Haven, CT 06510 203-272-2596; alexion.com New Haven, CT 1,000 Pharmaceuticals Severe and life-threatening rare disorders 1992 David Brennan (2) Interim CEO 4 Bristol-Myers Squibb Co. 5 Research Parkway Wallingford, CT 06492 (3) 203-677-6000; www.bms.com New York, NY 835 (4) Bio- manufacturing Genetics Pharmaceuticals BioPharma focused on discovering, developing and delivering medicines to help patients prevail over serious diseases such as cancer, cardiovascular disease, fibrotic diseases, genetically defined diseases, hepatitis C, HIV and rheumatoid arthritis 1858 Giovanni Caforio CEO 5 PerkinElmer Inc. 710 Bridgeport Ave. Shelton, CT 06484 (5) 203-925-4600; www.perkinelmer.com Waltham, MA 500 Bio-informatics Human and environmental health 1937 Robert F. Friel Chairman & CEO 5 Purdue Pharma LP 1 Stamford Forum, 201 Tresser Blvd. Stamford, CT 06901 800-745-7445; www.purduepharma.com Stamford, CT 500 (6) Medical Pharmaceuticals Prescription and non-prescription medicines and hospital products; development of opioid pain medications with abuse- deterrent properties 1991 Mark Timney President & CEO 7 The Jackson Laboratory for Genomic Medicine (7) 10 Discovery Drive Farmington, CT 06032 860-837-2474; www.jax.org Bar Harbor, ME 200 Medical Genetics Discovery of genomic causes of disease and development of diagnostics and therapeutics 2014 (8) Charles Lee Scientific director 8 MannKind Corp. 1 Casper St. Danbury, CT 06810 203-798-8000; www.mannkindcorp.com Valencia, CA 168 Pharmaceuticals Inhalation product technologies 1991 Matthew J. Pfeffer CEO, CFO & director 9 Scapa Healthcare (9) 111 Great Pond Drive Windsor, CT 06095 860-688-8000; www.scapahealthcare.com Manchester, UK 100 Medical Bio- manufacturing Adhesive coated materials for the medical device, consumer wellness, advanced wound care and drug delivery fixation markets 1982 Joseph Davin President of health care 10 Protein Sciences Corp. 1000 Research Parkway Meriden, CT 06450 203-686-0800; proteinsciences.com Meriden, CT 90 Bio-engineering Pharmaceuticals Vaccine development and protein production 1983 Manon M. J. Cox President & CEO 11 Achillion Pharmaceuticals 300 George St. New Haven, CT 06511 203-624-7000; www.achillion.com New Haven, CT 80 Pharmaceuticals Therapy for chronic hepatitis C and a platform of specific complement factor D inhibitors 2000 Milind S. Deshpande President & CEO 12 Core Informatics 36 E. Industrial Road, 2nd floor Branford, CT 06405 866-823-0337; www.coreinformatics.com Branford, CT 62 Bio-informatics Data management and lab informatics solutions built on the platform for science 2005 Josh Geballe CEO 13 Transgenomic Inc. 5 Science Park New Haven, CT 06511 203-907-2201; www.transgenomic.com Omaha, NE 55 Genetics Genetic testing 1997 Paul Kinnon President & CEO 14 Kolltan Pharmaceuticals Inc. 300 George St., Suite 530 New Haven, CT 06511 203-773-3000; www.kolltan.com New Haven, CT 41 Pharmaceuticals Biologics targeting receptor tyrosine kinases for oncology and immunology 2008 Gerald McMahon President & CEO 15 Ce3 Inc. 246 Goose Lane, Suite 202 Guilford, CT 06437 203-404-7500; www.ce3inc.com Guilford, CT 40 Medical Contract research focused on providing biotechnology companies with phase 1 and 2 clinical trial execution and regulatory submission services 2005 Holly Ohanesian Coulter President & CEO 15 Melinta Therapeutics Inc. 300 George St., Suite 301 New Haven, CT 06511 203-624-5606; www.melinta.com Lincolnshire, IL 40 Pharmaceuticals Discovery, development and commercialization of antibiotics to overcome resistant, life-threatening infections 2000 Eugene Sun Interim CEO 17 Arvinas Inc. 5 Science Park New Haven, CT 06511 203-535-1456; www.arvinas.com New Haven, CT 30 Medical Development of therapeutics to treat a variety of diseases including cancer, pro-inflammatory, autoimmune and rare disease 2013 Manuel Litchman President & CEO 17 NanoViricides Inc. 1 Controls Drive Shelton, CT 06484 203-937-6137; www.nanoviricides.com Shelton, CT 30 Pharmaceuticals Nanotechnology-based biomimetic anti-viral medicines targeting influenzas, bird flu, HIV/AIDS, cold sores, genital herpes infection, viral eye diseases, ebola and dengue viruses 2005 Eugene Seymour, CEO Anil R. Diwan President & chairman 19 CARA Therapeutics 1 Parrott Drive Shelton, CT 06484 203-567-1500; www.caratherapeutics.com Shelton, CT 22 Medical Development of therapeutics to treat human diseases associated with pain, inflammation and pruritus 2004 Derek Chalmers Director, president & CEO Source: CURE, each company via survey. Notes: R&D = research and development, DND = did not disclose. Marinus Pharmaceuticals Inc. closed its New Haven office. Biodel Inc. expects to cease operations in Danbury in 2016. Hologic Inc., Medtronic and New Haven Pharmaceuticals do not disclose employee data by geographic location. AxioMx Inc. (Abcam plc), Becton Dickinson, Charles River Laboratories International Inc., CooperSurgical Inc., Gilead Connecticut Inc., Icahn School of Medicine Mount Sinai Genomics Research Center and Idexx Laboratories were contacted but did not complete a survey. (1) On Feb. 19, 2016, an upcoming layoff was announced at the Ridgefield facility without quantifying the scope of the workforce reduction. (2) Took over as interim CEO in Dec. 2016 upon the resignation of David L. Hallal. (3) In early 2018, BMS plans to close Wallingford site and move 900-plus employees to other locations in Connecticut and Cambridge, Mass. (4) Figure excludes field-based personnel. (5) With an additional R&D operation in Branford. (6) Figure is from 2015. (7) On the campus of University of Connecticut Health Center. (8) Year founded for the Farmington site. The Jackson Laboratory was founded in 1929. (9) Formerly Scapa Tapes North America LLC. —Compiled by Stephanie R. Meagher.

• Cover